Global Viral Vector Manufacturing for Gene Therapy Market Growth (Status and Outlook) 2024-2030

Global Viral Vector Manufacturing for Gene Therapy Market Growth (Status and Outlook) 2024-2030

Viral Vector Manufacturing for Gene Therapy refers to the specialized process of producing viral vectors, which are engineered viruses used to deliver therapeutic genetic material into patients' cells. This process involves several stages, including design, production, purification, and quality control, to ensure that the viral vectors are safe, effective, and compliant with regulatory standards.

Viral vector manufacturing is crucial for the development and delivery of gene therapies, which aim to treat genetic disorders, cancers, and other diseases by introducing, removing, or altering genetic material within a patient’s cells. The manufacturing process ensures that these therapies are safe, effective, and ready for clinical use.

The global Viral Vector Manufacturing for Gene Therapy market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Viral Vector Manufacturing for Gene Therapy Industry Forecast” looks at past sales and reviews total world Viral Vector Manufacturing for Gene Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Viral Vector Manufacturing for Gene Therapy sales for 2023 through 2029. With Viral Vector Manufacturing for Gene Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Viral Vector Manufacturing for Gene Therapy industry.

This Insight Report provides a comprehensive analysis of the global Viral Vector Manufacturing for Gene Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Viral Vector Manufacturing for Gene Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Viral Vector Manufacturing for Gene Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Viral Vector Manufacturing for Gene Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Viral Vector Manufacturing for Gene Therapy.

United States market for Viral Vector Manufacturing for Gene Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Viral Vector Manufacturing for Gene Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Viral Vector Manufacturing for Gene Therapy is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Viral Vector Manufacturing for Gene Therapy players cover Thermo Fisher Scientific, Lonza, Catalent, Charles River, Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Viral Vector Manufacturing for Gene Therapy market by product type, application, key players and key regions and countries.

Segmentation by Type:
AAV
Lentivirus
Adenovirus
HSV
Others

Segmentation by Application:
Vaccine Development
Gene Therapy
Academic Scientific Research Institution
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
AAV
Lentivirus
Adenovirus
HSV
Others

Segmentation by Application:
Vaccine Development
Gene Therapy
Academic Scientific Research Institution
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Thermo Fisher Scientific
Lonza
Catalent
Charles River
Merck
SK pharmteco
Oxford Biomedica
AGC Biologics（MolMed）
Gene Universal
Polyplus (Sartorius)
CCRM
FUJIFILM Diosynth Biotechnologies
Biovian
Miltenyi Bioindustry
Aldevron
Takara Bio
Yposkesi
Genezen
Exthera
Flash Therapeutics
VIVEBiotech
FinVector
Eurogentec
VGXI
GenScript ProBio
EurekaBio
Obio Technology
GeneSail Biotech
VectorBuilder
WuXi ATU
Ubrigene
Porton Biologics
Pharmaron
PackGene Biotechnology
Hillgene
Asymchem

Please note: The report will take approximately 2 business days to prepare and deliver.